Newsroom – Freya

The Freya Newsroom

Find out the latest about Freya. Announcements, press coverage, and company info—it’s all here.

"Women's health biotech to move lead compound into IVF patients after early-stage win"

"Freya Biosciences is leading the charge in women's health, using groundbreaking immunotherapies to address fertility and reproductive issues that have long been underfunded and underdeveloped."

"…has the potential of becoming the first targeted therapy for the IVF population with vaginal dysbiosis."

"…Freya and a major U.S. clinic, Boston IVF, support the concept of lower pregnancy rates in women with a dysbiotic inflammatory vaginal microbiome…"

"Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis"

"Freya is also developing candidates to tackle preterm birth and infertility caused by endometriosis."

"The findings show promise for improving fertility outcomes, particularly in in vitro fertilization (IVF) procedures."

"A former WHO epidemiologist is applying lessons learned during the Ebola epidemic … at the forefront of women’s health: the reproductive microbiome."

"Freya Biosciences, a Danish and US biotech named after the Norse goddess of fertility, has raised a $38 million Series A."

“Tackling what has long been a taboo subject, the biotech startup is studying and optimising the vaginal microbiome in ways that are truly innovative. "

Press releases

19th November, 2024

Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment

Freya Biosciences secures a $10.4 million strategic investment from the Bill & Melinda Gates Foundation, along with additional funding from EIFO, to expand its DYSCOVER™ platform for microbial immunotherapies targeting bacterial vaginosis and preterm birth prevention.

12th December, 2023

Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies

Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.

27th June, 2023

Freya Biosciences Announces Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic.